BRC BIOTECHNOLOGY（Chinese：博瑞策生物） (Shanghai) Co., Ltd. (referred to as "BRC BIOTECHNOLOGY"), a professional provider of biobsecurity testing services, recently announced the completion of a Pre-A round financing exceeding RMB 100 million.（ USD 15.5 million）
According to the official website, BRC BIOTECHNOLOGY is a biobsecurity testing service provider dedicated to offering professional and compliant biobsecurity testing, methodology development, target validation evaluation, and related assay kit products in areas such as cell and gene therapy, antibodies, nucleic acid drugs, and more.
Since its establishment in June 2022, BRC BIOTECHNOLOGY has successfully completed the construction, validation, and operation of a testing service platform spanning approximately 6,000 square meters, which complies with cGMP and Biosafety Level 2 (BSL-2) standards in China, the United States, and Europe, within a "100-day project" timeframe. As of the time of writing, BRC BIOTECHNOLOGY has obtained compliance certifications including ISO9001:2015, CMA, BSL-1, and BSL-2, and has successfully passed compliance audits conducted by dozens of leading domestic and international biopharmaceutical companies.
Now the global biopharmaceutical industry is currently experiencing a trend of concentrated development, mainly concentrated in countries and regions such as the United States, Europe, Japan, India, Singapore, and China. Looking at China's biopharmaceutical industry, it started to develop only in the 1980s and has since grown rapidly.
In addition, BRC BIOTECHNOLOGY has achieved exclusive cooperation with Cergentis, a Dutch testing company, in the Chinese market, and strategic cooperation with SGS Life Sciences in Northeast Asia. These strong alliances aim to bring better technology and services to the market and customers, accelerate overseas expansion, and explore international markets. While building a high-performance local service platform, BRC BIOTECHNOLOGY also aims to enhance its international influence, support the high-quality development of the biopharmaceutical industry, and safeguard clinical medication and patient health.
BRC BIOTECHNOLOGY has independently developed a platform that has completed the development and compliance verification of hundreds of methodologies. They have also submitted applications for several patent achievements. The company offers comprehensive biobsecurity testing solutions for various forms of drugs, including antibody drugs, vaccine products, nucleic acid drugs, stem cell products, and cell gene therapy. With a commitment to ensuring the quality and safety of biopharmaceuticals, BRC BIOTECHNOLOGY has achieved several tens of millions of RMB in order collaborations in the past three months and has successfully delivered several IND and overseas BLA projects.
The biopharmaceutical sector has attracted numerous companies, and the biopharmaceutical industry is a strategic emerging industry and an important component of the pharmaceutical industry. In terms of market capitalization, there are companies with a market capitalization of over CNY 200 billion , such as WuKi AppTec（Chinese：药明康德） and Hearem（Chinese：恒瑞医药）; companies with a market capitalization between CNY 100 billion and 200 billion , such as ZFSW the Biologics Compamy（Chinese：智飞生物）, BeiGene（Chinese：百济神州）, WANTAI BioPharm（Chinese：万泰生物）, FOSUNPHARMA（Chinese：复星医药）, and Tasly Pharmaceutical（Chinese：泰格医药）; and companies with a market capitalization below CNY 100 billion , such as CHANGCHUN HIGH-TECH（Chinese：长春高新）, ASYMCHEM（Chinese：凯莱英） walvax（Chinese：沃森生物）, and Hualan Biological（Chinese：华兰生物）, among others.
BRC BIOTECHNOLOGY has recently completed a Pre-A round financing, with LEGEND Capital leading the investment and several other funds participating as well. With this round, the company has raised a total of nearly 200 million RMB within less than a year. The funds raised in this round will primarily be used to accelerate the expansion of their cGMP-compliant biobsecurity testing platform, supporting BRC BIOTECHNOLOGY in continuously improving its high-quality biosecurity industry layout and ensuring the quality and safety of domestic biopharmaceuticals.x